Promising Clinical Data Supports the Value of Molecular Breast Imaging (MBI)
SALEM, NH (December 11, 2013) – A unique dual-head molecular breast imaging (MBI) system detected significantly more difficult-to-find cancers than traditional mammography according to a new study presented at the 99th Annual Radiological Society of North America (RSNA). Robin Shermis, MD of ProMedica Toledo Hospital Breast Care Center presented, Dedicated Dual-Head Molecular Breast Imaging (MBI) as an Adjunct to Mammography in Patients with Dense Breast Tissue and/or Elevated Risk for Breast Cancer, which evaluated patients retrospectively using the LumaGEM® MBI system from Gamma Medica. More than four times as many cancers were seen on MBI (23 of 125) than were on mammography (5 of 125).
“MBI deserves greater attention in the arena of adjunct breast screening given its performance, ease of use and low cost. As the discussion of breast tissue density continues to gain more attention and requirements for adjunctive screening proliferate, MBI should be part of the solution,” Dr. Shermis concluded.
About Gamma Medica, Inc.
Gamma Medica, Inc. is dedicated to the development of advanced digital imaging technologies that address the growing importance of overcoming the critical shortcomings of mammography and other screening modalities in the early detection of breast cancer. The company designs, builds and services the LumaGEM® MBI system, the first commercially available, FDA-cleared planar, dual head, fully
solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular
breast imaging.